CRNX - Crinetics Pharmaceuticals, Inc.
NEXT EARNINGS:
Feb 26, 2026
(in 1 day)
EPS Est: $-1.40
|
Rev Est: $4.7M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$94.71
DETAILS
HIGH:
$143.00
LOW:
$67.00
MEDIAN:
$87.00
CONSENSUS:
$94.71
UPSIDE:
112.74%
Market Cap:
4.56B
Volume:
609,167
Avg Volume:
1,199,125
52 Week Range:
24.1-57.99
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.19
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
437
IPO Date:
2018-07-18
EPS (TTM):
-3.69
P/E Ratio:
-13.84
Revenue (TTM):
1.04M
Total Assets:
1.43B
Total Debt:
51.72M
Cash & Equiv:
264.55M
Rev Growth (5Y):
-2.7%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-24.6%
Debt/Equity:
0.04
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-06 | $-1.38 | $-1.27 | -8.7% | $143000 | $4.3M | -96.7% |
| 2025-08-07 | $-1.23 | $-1.13 | -8.8% | $1.0M | $394000 | +161.7% |
| 2025-05-08 | $-1.04 | $-0.99 | -5.1% | $361000 | $347910 | +3.8% |
| 2025-02-27 | $-0.88 | $-0.92 | +4.3% | — | $727270 | — |
| 2024-11-12 | $-0.96 | $-0.91 | -5.4% | — | $218091 | — |
| 2024-08-08 | $-0.94 | $-0.86 | -9.3% | $399000 | $510000 | -21.8% |
| 2024-05-09 | $-0.93 | $-0.84 | -10.7% | $640000 | $260000 | +146.2% |
| 2024-02-28 | $-0.90 | $-0.89 | -1.1% | — | $260000 | — |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.04M | 4.01M | 4.74M | 1.08M | 71,000 | 1.19M | 2.43M | 2.04M | 589,000 |
| Net Income | (298.41M) | (214.53M) | (163.92M) | (107.64M) | (73.81M) | (49.53M) | (27.11M) | (9.16M) | (6.02M) |
| EPS | -3.69 | -3.69 | -3.15 | -2.80 | -2.42 | -2.05 | -2.23 | -0.66 | -0.43 |
| Total Assets | 1.43B | 635.35M | 352.18M | 351.01M | 183.44M | 130.38M | 171.41M | 15.60M | 12.60M |
| Total Debt | 51.72M | 51.73M | 3.08M | 3.07M | 4.01M | 5.57M | 0 | 0 | 212,000 |
| Cash & Equivalents | 264.55M | 54.90M | 32.67M | 200.69M | 93.09M | 40.33M | 44.97M | 14.19M | 12.15M |
| Operating Cash Flow | (225.97M) | (166.31M) | (115.20M) | (88.59M) | (62.03M) | (46.38M) | (19.46M) | (9.48M) | (5.47M) |
| Free Cash Flow | (229.81M) | (171.00M) | (116.86M) | (89.02M) | (62.21M) | (46.87M) | (20.52M) | (9.78M) | (5.66M) |
| FCF per Share | -2.84 | -2.94 | -2.25 | -2.32 | -2.04 | -1.94 | -1.69 | -0.70 | -0.41 |
| Book Value | 1.32B | 539.11M | 316.33M | 331.94M | 168.92M | 117.14M | (43.38M) | (15.02M) | (6.20M) |
| Cash & ST Investments | 1.35B | 558.55M | 334.43M | 333.71M | 170.88M | 118.39M | 163.88M | 14.19M | 12.15M |
| ROC Equity | -0.23 | -0.40 | -0.52 | -0.32 | -0.44 | -0.42 | N/A | N/A | N/A |